bioRxiv Science⌕ Search

Biology subjects

Alexis, A.

Publications and source records attributed to Alexis, A..

2 recordsLinked to original sources

A multi-faceted analysis of synapses reveals the role of neuroligin-1 cleavage in presynaptic vesicle accumulation in the lateral amygdala

Neuroligin-1 (NLGN1) is a cell adhesion molecule found at excitatory glutamatergic synapses in the brain which regulates synaptic function and maturation. Extracellular cleavage of NLGN1 by proteases has been shown to control vesicle release in cultured neurons, but nothing is known about the underlying changes to synapse structure that accompany this, or how synapse function is affected in brain tissue. We found that prevention of NLGN1 cleavage through mutation to the extracellular stalk domain increases synaptic vesicle docking and miniature excitatory post-synaptic current frequency at synapses of the lateral amygdala. Using a novel volume electron microscopy (vEM) analysis pipeline based on deep learning extraction of thousands of synapses and vesicles clouds and subsequent spatial analyses, we found that the total pool of synaptic vesicles shifts closer to the synapse in mutants. Furthermore, we observed an increased frequency of incomplete synapses that lack vesicle accumulation, pointing towards disruption of synaptic pruning and accumulation of putatively non-functioning synapses. Our study provides evidence of a structural and functional role of NLGN1 cleavage in native brain tissue, and establishes a foundation for vEM analysis of synapse-vesicle spatial relationships in other animal models of dysfunction and disease.

neuroscience↗

Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury

Multiple drugs to treat traumatic brain injury (TBI) have failed clinical trials. Most drugs lose efficacy as the time interval increases between injury and treatment onset. Insufficient therapeutic time window is a major reason underlying failure in clinical trials. Few drugs have been developed with therapeutic time windows sufficiently long enough to treat TBI because little is known about which brain functions can be targeted if therapy is delayed hours to days after injury. We identified multiple injury parameters that are improved by first initiating treatment with the drug combination minocycline (MINO) plus N-acetylcysteine (NAC) at 72 hours after injury (MN72) in a mouse closed head injury (CHI) experimental TBI model. CHI produces spatial memory deficits resulting in impaired performance on Barnes maze, hippocampal neuronal loss, and bilateral damage to hippocampal neurons, dendrites, spines and synapses. MN72 treatment restores Barnes maze acquisition and retention, protects against hippocampal neuronal loss, limits damage to dendrites, spines and synapses, and accelerates recovery of microtubule associated protein 2 (MAP2) expression, a key protein in maintaining proper dendritic architecture and synapse density. These data show that in addition to the structural integrity of the dendritic arbor, spine and synapse density can be successfully targeted with drugs first dosed days after injury. Retention of substantial drug efficacy even when first dosed 72 hours after injury makes MINO plus NAC a promising candidate to treat clinical TBI.

neuroscience↗